A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. This broad-spectrum, non-toxic antimicrobial agent is available in liquid form and various concentrations, distinguished by its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to develop resistance. Our SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, or EPA, the United States Food and Drug Administration, or FDA, and Health Canada. In addition to manufacturing and distributing these products, we also supply SDC-based formulations as raw material ingredients for personal care products.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.4M | 2.2M | 2.0M | - | 1.9M | 3.9M |
| Net Income | -2.2M | -2.4M | -3.4M | -4.0M | -3.5M | -2.3M |
| EPS | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.03 |
| Free Cash Flow | 0 | -2.0M | -2.6M | -3.3M | -2.5M | -1.7M |
| ROIC | -134.8% | -169.6% | -308.2% | -170.7% | -89.3% | -69.6% |
| Gross Margin | 60.7% | 59.2% | 58.7% | - | 54.0% | 52.8% |
| Debt/Equity | 0.00 | -1.02 | -1.03 | 3.75 | 0.15 | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.0M | -2.3M | -3.2M | -3.9M | -3.7M | -2.3M |
| Operating Margin | -86.0% | -103.2% | -162.6% | - | -201.0% | -58.8% |
| ROE | 0.0% | - | - | -1456.3% | -89.3% | -69.6% |
| Shares Outstanding | 112M | 120M | 112M | 99M | 87M | 77M |
PURE BIOSCIENCE, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 56.2%.
PURE BIOSCIENCE, INC. (PURE) has a 5-year average return on invested capital (ROIC) of -124.8%. This is below average and may indicate limited pricing power.
PURE BIOSCIENCE, INC. (PURE) has a market capitalization of $9M. It is classified as a small-cap stock.
PURE BIOSCIENCE, INC. (PURE) does not currently pay a regular dividend.
PURE BIOSCIENCE, INC. (PURE) operates in the Miscellaneous Chemical Products industry, within the Materials sector.
PURE BIOSCIENCE, INC. (PURE) reported annual revenue of $2 million in its most recent fiscal year, based on SEC EDGAR filings.
PURE BIOSCIENCE, INC. (PURE) has a net profit margin of -108.9%. The company is currently unprofitable.
PURE BIOSCIENCE, INC. (PURE) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PURE BIOSCIENCE, INC. (PURE) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
PURE BIOSCIENCE, INC. (PURE) has a 5-year average gross margin of 56.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for PURE BIOSCIENCE, INC. (PURE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PURE BIOSCIENCE, INC. (PURE) has a book value per share of $-0.04, based on its most recent annual SEC filing.